MBX Biosciences, Inc.

What they do

MBX uses its proprietary Precision Endocrine Peptide (PEP) platform to engineer peptide prodrugs with extended time-action profiles and low peak-to-trough concentration ratios, intended to allow less frequent dosing than existing therapies. The pipeline spans chronic hypoparathyroidism (lead candidate canvuparatide, or MBX 2109), obesity (MBX 4291, MBX 5765 and newly nominated MBX 6180), and post-bariatric hypoglycemia (imapextide, or MBX 1416). The company was founded by peptide drug design leaders and completed its IPO in September 2024. It has not generated any revenue from product sales.

Revenue drivers

• Canvuparatide (MBX 2109) — Lead candidate, a once-weekly parathyroid hormone prodrug for chronic hypoparathyroidism; no revenue today, with a Phase 3 pivotal trial recruiting as of the August 2026 update.
• Obesity portfolio (MBX 4291, MBX 5765, MBX 6180) — MBX 4291 is a GLP-1/GIP co-agonist prodrug in Phase 1; MBX 5765 (GLP-1/GIP/GCG/DACRA) and MBX 6180 (GLP-1/GIP/GCG) are nominated development candidates in IND-enabling studies. No revenue today.
• Imapextide (MBX 1416) — Once-weekly GLP-1 receptor antagonist that achieved proof of concept in post-bariatric hypoglycemia in the Phase 2a STEADI trial; the company will not commit further investment to a Phase 2b trial. No revenue today.
• Discovery-stage programs — Multiple programs in lead optimization; company stated it expected to nominate two additional candidates in the second and third quarters of 2026, and has since nominated MBX 5765 and MBX 6180.

Recent performance

Net loss was $87.0 million in 2025, versus $61.9 million in 2024 and $32.6 million in 2023. Operating cash use was $79.9 million in 2025, compared with $54.7 million in 2024 and $32.0 million in 2023. As of December 31, 2025, accumulated deficit was $224.5 million. The Q2 2026 earnings release reported $418.6 million in cash and investments, expected to support operations into 2029, while the June 30, 2026 balance sheet shows total assets of $435.9 million, total liabilities of $26.4 million and shareholder equity of $409.5 million. The company remains pre-revenue.

Strategy

MBX is prioritizing late-stage development of once-weekly canvuparatide, with a Phase 3 pivotal trial of once-weekly canvuparatide now recruiting after full Phase 2 and one-year open-label extension data were presented at ENDO 2026. In obesity, the company is expanding its pipeline and advancing MBX 4291, MBX 5765 and MBX 6180, each designed for potential once-monthly dosing. It reported preliminary blinded Phase 1 data for MBX 4291 showing mean weight loss of 7% (range 0-16%) at eight weeks in the first MAD Part B cohort (n=8, including 2 placebo). Following proof of concept for imapextide in PBH, the company stated it will not commit further investment toward a Phase 2b trial of imapextide, reallocating focus to its growing obesity pipeline.

Risks

• No approved products or revenue — MBX has no products approved for sale and has not generated any revenue from product sales, so profitability depends entirely on successful development and eventual commercialization of its candidates.
• Accumulating losses and cash use — Net loss rose to $87.0 million in 2025 from $61.9 million in 2024, with operating cash use of $79.9 million in 2025, and management expects significant and increasing operating losses for the foreseeable future.
• Early-stage clinical and regulatory risk — Lead programs remain in Phase 1/Phase 2 or earlier, and the company notes that preclinical results, such as body weight loss for MBX 4291 in mice, may not be predictive of later-stage clinical trial results.
• Pipeline reprioritization — MBX will not commit further investment toward a Phase 2b trial of imapextide despite proof of concept in PBH, illustrating that programs can be curtailed based on portfolio priorities.

Outlook

Management expects to initiate the Phase 3 pivotal trial of once-weekly canvuparatide in chronic hypoparathyroidism in Q3 2026, with sites activated and participants being recruited and screened. For MBX 4291, the company remains on track to report data from the first cohort of the 12-week MAD (Part C) in Q4 2026, with Cohort C1 evaluating a 30 mg once-weekly x4 plus 120 mg and 180 mg once-monthly titration regimen in adults with obesity (BMI >= 30). Preclinical data for MBX 6180 are expected at a scientific meeting in Q4 2026, while IND-enabling studies for MBX 5765 and MBX 6180 are ongoing. Management states $418.6 million in cash and investments is expected to support operations into 2029.